These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8638930)

  • 21. Endogenous sodium pump inhibitors in human urine. Further identification of inhibitors of Na-K-ATPase.
    Kramer HJ; Krampitz G; Bäcker A; Michel H; Krampitz G; Meyer-Lehnert H
    Am J Hypertens; 1995 Jul; 8(7):753-60. PubMed ID: 7546503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is the circulating ouabain-like compound ouabain?
    Gomez-Sanchez EP; Foecking MF; Sellers D; Blankenship MS; Gomez-Sanchez CE
    Am J Hypertens; 1994 Jul; 7(7 Pt 1):647-50. PubMed ID: 7946167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ouabainlike factor in Milan hypertensive rats.
    Ferrandi M; Minotti E; Salardi S; Florio M; Bianchi G; Ferrari P
    Am J Physiol; 1992 Oct; 263(4 Pt 2):F739-48. PubMed ID: 1329560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving the specificity of digoxin immunoassays.
    Valdes R
    Wien Klin Wochenschr Suppl; 1992; 191():55-9. PubMed ID: 1509756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of ouabain-like factor in normal and ischemic rat heart.
    D'Urso G; Frascarelli S; Balzan S; Zucchi R; Montali U
    J Cardiovasc Pharmacol; 2004 May; 43(5):657-62. PubMed ID: 15071352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of Na-K-ATPase in human urine: effects of ouabain-like factors and of vanadium-diascorbate on calcium mobilization in rat vascular smooth muscle cells: comparison with the effects of ouabain, angiotensin II, and arginine-vasopressin.
    Meyer-Lehnert H; Bäcker A; Kramer HJ
    Am J Hypertens; 2000 Apr; 13(4 Pt 1):364-9. PubMed ID: 10821337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of endogenous ouabain in culture supernatant of PC12 cells.
    Komiyama Y; Nishimura N; Munakata M; Mori T; Okuda K; Nishino N; Hirose S; Kosaka C; Masuda M; Takahashi H
    J Hypertens; 2001 Feb; 19(2):229-36. PubMed ID: 11212965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new digoxin immunoassay substantially free of interference by digoxin immunoreactive factor.
    Jiang F; Wilhite TR; Smith CH; Landt M
    Ther Drug Monit; 1995 Apr; 17(2):184-8. PubMed ID: 7624908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purification and characterization of endogenous digoxin-like immunoreactive factors in chicken blood.
    Wei JS; Cheng HC; Tsai KJ; Liu DH; Lee HH; Chiu DT; Liu TZ
    Life Sci; 1996; 59(19):1617-29. PubMed ID: 8913327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction.
    Balzan S; Neglia D; Ghione S; D'Urso G; Baldacchino MC; Montali U; L'Abbate A
    Eur J Heart Fail; 2001 Mar; 3(2):165-71. PubMed ID: 11246053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae.
    Fedorova OV; Tapilskaya NI; Bzhelyansky AM; Frolova EV; Nikitina ER; Reznik VA; Kashkin VA; Bagrov AY
    J Hypertens; 2010 Feb; 28(2):361-6. PubMed ID: 19927009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excretion of endogenous digoxin-like immunoreactive factors in human urine is a function of urine flow rate.
    Siegfried BA; Valdes R
    Clin Chem; 1988 May; 34(5):960-4. PubMed ID: 3370798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dialyzability and binding of digoxin-like immunoreactive factors (DLIF) with serum macromolecules in uremic patients on hemodialysis.
    Dasgupta A; Peng Y
    Life Sci; 1991; 49(22):1603-9. PubMed ID: 1943464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications.
    Valdes R
    Clin Chem; 1985 Sep; 31(9):1525-32. PubMed ID: 3896570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endogenous digoxin-like immunoreactive factors (DLIF) as measured by the CEDIA digoxin assay and a fluorescence polarization immunoassay.
    Schlebusch H; Jarausch J; Domke I
    Wien Klin Wochenschr Suppl; 1992; 191():59-66. PubMed ID: 1509757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
    Farr CD; Tabet MR; Ball WJ; Fishwild DM; Wang X; Nair AC; Welsh WJ
    J Med Chem; 2002 Jul; 45(15):3257-70. PubMed ID: 12109909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated blood levels of endogenous ouabain-like factor in preterm versus mature newborns at birth.
    Göõz M; Vakkuri O; de Châtel R; Szalay KS; Tóth M
    Biol Neonate; 2004; 85(3):155-8. PubMed ID: 14646339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of non-digitalis binding properties of digoxin-specific Fabs using direct binding methods.
    Pullen MA; Harpel MR; Danoff TM; Brooks DP
    J Immunol Methods; 2008 Jul; 336(2):235-41. PubMed ID: 18555269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ouabain is not detectable in human plasma.
    Lewis LK; Yandle TG; Lewis JG; Richards AM; Pidgeon GB; Kaaja RJ; Nicholls MG
    Hypertension; 1994 Nov; 24(5):549-55. PubMed ID: 7960012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids.
    Pullen MA; Brooks DP; Edwards RM
    J Pharmacol Exp Ther; 2004 Jul; 310(1):319-25. PubMed ID: 14982968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.